Form 4: NextCure Director Stephen W. Webster Granted Stock Options

NextCure, Inc. Director Stephen W. Webster was granted 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

Summary

• Stephen W. Webster, a Director of NextCure, Inc. (NXTC), was granted stock options on June 20, 2025.
• He acquired 18,700 stock options, each representing the right to buy one share of Common Stock.
• The exercise price for these options is $0.47 per share.
• The options are set to vest in full on the earlier of June 20, 2026, and the date of the 2026 Annual Meeting of Stockholders.
• The expiration date for these stock options is June 19, 2035.
• Following this transaction, Mr. Webster beneficially owns 18,700 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's interests with shareholder value creation, incentivizing long-term performance. It is a routine compensation event.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $0.47 is relatively low, indicating potential for significant upside if the stock price increases.

Future Outlook

The stock options granted are set to vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders, indicating a future milestone for the director's equity compensation.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, common for aligning executive and board interests with long-term company performance.

Related Party Transactions

• The grant of stock options to Stephen W. Webster, a Director of NextCure, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Management: Stephen W. Webster, as a director, is part of the governance structure, and this grant incentivizes his oversight.

Next Steps

• The options will vest on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Stephen W. Webster may exercise these options at any time after vesting until the expiration date of June 19, 2035.

Key Dates

Recommendation

Keywords

NextCure, NXTC, Stock Options, Director, Stephen W. Webster, SEC Form 4, Insider Transaction, Equity Compensation